ReviewFrontiers in oncology2025
Antibody-drug conjugate: a newly developed biological missile for tumor treatment.
Review in Frontiers in oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
8 citing papers in PubMed.
- Physicochemical and Metabolic Optimization of NAMPT Inhibitors Enables Effective Antibody-Drug Conjugates for Liquid and Solid Tumors.ACS bio & med chem Au · 2026Article
- Infectious Complications of Antibody-Drug Conjugates: A Review of Safety Data from FDA-Approved Agents.Current oncology reports · 2026Review
- B7-H4-targeted radiotheranostics enable precise imaging and potent therapy across solid tumor models.Science advances · 2026Article
- Toxicities of Antibody-Drug Conjugates in Breast Cancer: From Mechanistic Insights to Clinical Management.Pharmaceutics · 2026Review
- Antibody-Drug Conjugates Beyond HER2 in Non-Small Cell Lung Cancer (NSCLC): Mechanisms, Emerging Targets, and Future Directions.Biomolecules · 2026Review
- CLL-1: An emerging target for immunotherapy in acute myeloid leukemia.Annals of hematology · 2026Review
- Review
- Effect of Endocytosis Inhibitors on the Cytotoxicity and Antitumor Activity of Anti-GD2 ADCs.Acta naturaeArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Antibody-drug conjugates (ADCs) represent one of the most advanced drug configurations under current research, primarily composed of a monoclonal antibody (mAb), a highly potent cytotoxic payload, and a linker that connects the drug to the antibody. The mAb serves mainly as a targeting moiety, guiding the conjugate to specific cells. The cytotoxic payload is responsible for the anticancer activity, whereas the linker ensures stable attachment between the antibody and the payload during circulation. The core advantage of ADCs lies in their ability to leverage the specificity of antibodies to deliver highly potent cytotoxic agents precisely to tumor cells, thereby significantly improving the therapeutic index. However, they also face challenges such as systemic toxicity, drug resistance, tumor heterogeneity, and complex manufacturing processes. Currently, extensive research is focused on technological innovations, the development of novel ADCs, and the optimization of clinical combination therapies. This article provides a comprehensive review of the structure and mechanism of action of ADCs, their developmental history, current challenges, emerging novel agents, and combination strategies with immune checkpoint inhibitors (ICIs).
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.